Aiming for precision: personalized medicine through sepsis subtyping

Abstract

According to the latest definition, sepsis is characterized by life-threatening organ dysfunction caused by a dysregulated host response to an infection. However, this definition fails to grasp the heterogeneous nature and the underlying dynamic pathophysiology of the syndrome. In response to this heterogeneity, efforts have been made to stratify sepsis patients into subtypes, either based on their clinical presentation or pathophysiological characteristics. Subtyping introduces the possibility of the implementation of personalized medicine, whereby each patient receives treatment tailored to their individual disease manifestation. This review explores the currently known subtypes, categorized by subphenotypes and endotypes, as well as the treatments that have been researched thus far in the context of sepsis subtypes and personalized medicine.

Keywords

Sepsis / Subtyping / Immune response

References

[1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315: 801-10. https://doi.org/10.1001/jama.2016.0287.

[2] Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the global burden of disease study. Lancet Lond Engl. 2020; 395: 200-11. https://doi.org/10.1016/S0140-6736(19)32989-7.

[3] Giamarellos-Bourboulis EJ, Aschenbrenner AC, Bauer M, Bock C, Calandra T, Gat-Viks I, et al. The pathophysiology of sepsis and precision-medicine-based immunotherapy. Nat Immunol. 2024; 25: 19-28. https://doi.org/10.1038/s41590-023-01660-5.

[4] Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019-results from a systematic review and meta-analysis. Crit Care Lond Engl. 2020; 24: 239. https://doi.org/10.1186/s13054-020-02950-2.

[5] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47: 1181-247. https://doi.org/10.1007/s00134-021-06506-y.

[6] Marshall JC.Why have clinical trials in sepsis failed? Trends Mol Med. 2014; 20: 195-203. https://doi.org/10.1016/j.molmed.2014.01.007.

[7] Slim MA, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T, et al. Towards personalized medicine: a scoping review of immunotherapy in sepsis. Crit Care. 2024; 28: 183. https://doi.org/10.1186/s13054-024-04964-6.

[8] Harhay MO, Wagner J, Ratcliffe SJ, Bronheim RS, Gopal A, Green S, et al. Outcomes and statistical power in adult critical care randomized trials. Am J Respir Crit Care Med. 2014; 189: 1469-78. https://doi.org/10.1164/rccm.201401-0056CP.

[9] Goh C, Knight JC. Enhanced understanding of the host-pathogen interaction in sepsis: new opportunities for omic approaches. Lancet Respir Med. 2017; 5: 212-23. https://doi.org/10.1016/S2213-2600(17)30045-0.

[10] Leligdowicz A, Matthay MA. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit Care Lond Engl. 2019; 23: 80. https://doi.org/10.1186/s13054-019-2372-2.

[11] Shankar-Hari M, Calandra T, Soares MP, Bauer M, Wiersinga WJ, Prescott HC, et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respir Med. 2024; 12: 323-36. https://doi.org/10.1016/S2213-2600(23)00468-X.

[12] Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in ICU. Am J Respir Crit Care Med. 2024; 210: 155-66. https://doi.org/10.1164/rccm.202311-2086SO.

[13] Drawnel FM, Zhang JD, Küng E, Aoyama N, Benmansour F, Araujo Del Rosario A, et al. Molecular phenotyping combines molecular information, biological relevance, and patient data to improve productivity of early drug discovery. Cell Chem Biol. 2017; 24: 624-634.e3. https://doi.org/10.1016/j.chembiol.2017.03.016.

[14] Shivade C, Raghavan P, Fosler-Lussier E, Embi PJ, Elhadad N, Johnson SB, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc. 2014; 21: 221-30. https://doi.org/10.1136/amiajnl-2013-001935.

[15] Van Der PT, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021; 54: 2450-64. https://doi.org/10.1016/j.immuni.2021.10.012.

[16] Stanski NL, Wong HR. Prognostic and predictive enrichment in sepsis. Nat Rev Nephrol. 2020; 16: 20-31. https://doi.org/10.1038/s41581-019-0199-3.

[17] Shankar-Hari M, Rubenfeld GD. Population enrichment for critical care trials: phenotypes and differential outcomes. Curr Opin Crit Care. 2019; 25: 489-97. https://doi.org/10.1097/MCC.0000000000000641.

[18] Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011; 365: 1088-98. https://doi.org/10.1056/NEJMoa1106469.

[19] Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-84. https://doi.org/10.1056/NEJMoa052122.

[20] DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis subclasses: a framework for development and interpretation. Crit Care Med. 2021; 49: 748-59. https://doi.org/10.1097/CCM.0000000000004842.

[21] Seymour CW, Kennedy JN, Wang S, Chang CCH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019; 321: 2003-17. https://doi.org/10.1001/jama.2019.5791.

[22] Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019; 200: 327-35. https://doi.org/10.1164/rccm.201806-1197OC.

[23] Zhang Z, Zhang G, Goyal H, Mo L, Hong Y. Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: a latent profile analysis. Crit Care Lond Engl. 2018; 22: 347. https://doi.org/10.1186/s13054-018-2279-3.

[24] Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015; 41: 814-22. https://doi.org/10.1007/s00134-015-3764-7.

[25] Gårdlund B, Dmitrieva NO, Pieper CF, Finfer S, Marshall JC, Taylor TB. Six subphenotypes in septic shock: latent class analysis of the PROWESS shock study. J Crit Care. 2018; 47: 70-9. https://doi.org/10.1016/j.jcrc.2018.06.012.

[26] Aldewereld ZT, Zhang LA, Urbano A, Parker RS, Swigon D, Banerjee I, et al. Identification of clinical phenotypes in septic patients presenting with hypotension or elevated lactate. Front Med. 2022; 9: 1-14, 794423. https://doi.org/10.3389/fmed.2022.794423.

[27] Fohner AE, Greene JD, Lawson BL, Chen JH, Kipnis P, Escobar GJ, et al. Assessing clinical heterogeneity in sepsis through treatment patterns and machine learning. J Am Med Inform Assoc. 2019; 26: 1466-77. https://doi.org/10.1093/jamia/ocz106.

[28] Angus DC. Opening the debate on the new sepsis definition defining sepsis: a case of bounded rationality and fuzzy thinking? Am J Respir Crit Care Med. 2016; 194: 14-5. https://doi.org/10.1164/rccm.201604-0879ED.

[29] Schuler A, Wulf DA, Lu Y, Iwashyna TJ, Escobar GJ, Shah NH, et al. The impact of acute organ dysfunction on long-term survival in sepsis. Crit Care Med. 2018; 46: 843-9. https://doi.org/10.1097/CCM.0000000000003023.

[30] Sinha P, Meyer NJ, Calfee CS. Biological phenotyping in sepsis and acute respiratory distress syndrome. Annu Rev Med. 2023; 74: 457-71. https://doi.org/10.1146/annurev-med-043021-014005.

[31] Reddy K, Sinha P, O’Kane CM, Gordon AC, Calfee CS, McAuley DF. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020; 8: 631-43. https://doi.org/10.1016/S2213-2600(20)30124-7.

[32] Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, et al. Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med. 2009; 7: 34. https://doi.org/10.1186/1741-7015-7-34.

[33] Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016; 4: 259-71. https://doi.org/10.1016/S2213-2600(16)00046-1.

[34] Kwok AJ, Allcock A, Ferreira RC, Cano-Gamez E, Smee M, Burnham KL, et al. Neutrophils and emergency granulopoiesis drive immune suppression and an extreme response endotype during sepsis. Nat Immunol. 2023; 24: 767-79. https://doi.org/10.1038/s41590-023-01490-5.

[35] Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med. 2017; 196: 328-39. https://doi.org/10.1164/rccm.201608-1685OC.

[36] Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, et al. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018; 46: 915-25. https://doi.org/10.1097/CCM.0000000000003084.

[37] Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017; 5: 816-26. https://doi.org/10.1016/S2213-2600(17)30294-1.

[38] Baghela A, Pena OM, Lee AH, Baquir B, Falsafi R, An A, et al. Predicting sepsis severity at first clinical presentation: the role of endotypes and mechanistic signatures. eBioMedicine. 2022; 75: 103776. https://doi.org/10.1016/j.ebiom.2021.103776.

[39] Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primer. 2019; 5: 18. https://doi.org/10.1038/s41572-019-0069-0.

[40] Sinha P, Kerchberger VE, Willmore A, Chambers J, Zhuo H, Abbott J, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023; 11: 965-74. https://doi.org/10.1016/S2213-2600(23)00237-0.

[41] Maslove DM, Tang B, Shankar-Hari M, Lawler PR, Angus DC, Baillie JK, et al. Redefining critical illness. Nat Med. 2022; 28: 1141-8. https://doi.org/10.1038/s41591-022-01843-x.

[42] Neyton LPA, Sinha P, Sarma A, Mick E, Kalantar K, Chen S, et al. Host and microbe blood metagenomics reveals key pathways characterizing critical illness phenotypes. Am J Respir Crit Care Med. 2024; 209: 805-15. https://doi.org/10.1164/rccm.202308-1328OC.

[43] Torres LK, Pickkers P, van der Poll T. Sepsis-induced immunosuppression. Annu Rev Physiol. 2022; 84: 157-81. https://doi.org/10.1146/annurev-physiol-061121-040214.

[44] Bodinier M, Peronnet E, Brengel-Pesce K, Conti F, Rimmelé T, Textoris J, et al. Monocyte trajectories endotypes are associated with worsening in septic patients. Front Immunol. 2021; 12: 795052. https://doi.org/10.3389/fimmu.2021.795052.

[45] Mosevoll KA, Skrede S, Markussen DL, Fanebust HR, Flaatten HK, Aßmus J, et al. Inflammatory mediator profiles differ in sepsis patients with and without Bacteremia. Front Immunol. 2018; 9: 691. https://doi.org/10.3389/fimmu.2018.00691.

[46] Cajander S, Kox M, Scicluna BP, Weigand MA, Mora RA, Flohé SB, et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respir Med. 2024; 12: 305-22. https://doi.org/10.1016/S2213-2600(23)00330-2.

[47] van Amstel RBE, Kennedy JN, Scicluna BP, Bos LDJ, Peters-Sengers H, Butler JM, et al. Uncovering heterogeneity in sepsis: a comparative analysis of subphenotypes. Intensive Care Med. 2023; 49: 1360-9. https://doi.org/10.1007/s00134-023-07239-w.

[48] Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013; 309: 1154-62. https://doi.org/10.1001/jama.2013.2194.

[49] Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344: 699-709. https://doi.org/10.1056/NEJM200103083441001.

[50] Investigators PCESS, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014; 370: 1683-93. https://doi.org/10.1056/NEJMoa1401602.

[51] Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial. Am J Respir Crit Care Med. 2019; 199: 980-6. https://doi.org/10.1164/rccm.201807-1419OC.

[52] Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016; 316: 509-18. https://doi.org/10.1001/jama.2016.10485.

[53] Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, et al. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med. 2004; 169: 1144-51. https://doi.org/10.1164/rccm.200309-1329OC.

[54] van de Garde MDB, Martinez FO, Melgert BN, Hylkema MN, Jonkers RE, Hamann J. Chronic exposure to glucocorticoids shapes gene expression and modulates innate and adaptive activation pathways in macrophages with distinct changes in leukocyte attraction. J Immunol1950. 2014; 192: 1196-208. https://doi.org/10.4049/jimmunol.1302138.

[55] Leung DYM, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003; 111: 3-22quiz 23. https://doi.org/10.1067/mai.2003.97.

[56] Olnes MJ, Kotliarov Y, Biancotto A, Cheung F, Chen J, Shi R, et al. Corrigendum: Effects of systemically administered hydrocortisone on the human immunome. Sci Rep. 2016; 6: 25215. https://doi.org/10.1038/srep25215.

[57] Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018; 378: 797-808. https://doi.org/10.1056/NEJMoa1705835.

[58] Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018; 378: 809-18. https://doi.org/10.1056/NEJMoa1705716.

[59] Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, Dimopoulos G, Pantazi A, Orfanos SE, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017; 15: 172. https://doi.org/10.1186/s12916-017-0930-5.

[60] Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022; 3: 100817. https://doi.org/10.1016/j.xcrm.2022.100817.

[61] Kotsaki A, Pickkers P, Bauer M, Calandra T, Lupse M, Wiersinga WJ, et al. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open. 2022; 12:e067251. https://doi.org/10.1136/bmjopen-2022-067251.

[62] DeMerle KM, Kennedy JN, Chang CCH, Delucchi K, Huang DT, Kravitz MS, et al. Identification of a hyperinflammatory sepsis phenotype using protein biomarker and clinical data in the ProCESS randomized trial. Sci Rep. 2024; 14: 6234. https://doi.org/10.1038/s41598-024-55667-5.

[63] Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012; 366: 2055-64. https://doi.org/10.1056/NEJMoa1202290.

[64] Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019; 321: 1993-2002. https://doi.org/10.1001/jama.2019.5358.

[65] Goto T, Kudo D, Uchimido R, Hayakawa M, Yamakawa K, Abe T, et al. Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries. Crit Care. 2022; 26: 145. https://doi.org/10.1186/s13054-022-04020-1.

[66] Pickkers P, Angus DC, Bass K, Bellomo R, van den Berg E, Bernholz J, et al. Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL). Intensive Care Med. 2024; 50: 68-78. https://doi.org/10.1007/s00134-023-07271-w.

[67] Bruse N, Pardali K, Kraan M, Kox M, Pickkers P, the REVIVAL investigators. Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury. Crit Care. 2024; 28: 50. https://doi.org/10.1186/s13054-024-04837-y.

[68] Qiu X, Li J, Bonenfant J, Jaroszewski L, Mittal A, Klein W, et al. Dynamic changes in human single-cell transcriptional signatures during fatal sepsis. J Leukoc Biol. 2021; 110: 1253-68. https://doi.org/10.1002/JLB.5MA0721-825R.

[69] Balch JA, Chen UI, Liesenfeld O, Starostik P, Loftus TJ, Efron PA, et al. Defining critical illness using immunological endotypes in patients with and without sepsis: a cohort study. Crit Care. 2023; 27: 292. https://doi.org/10.1186/s13054-023-04571-x.